Novavax(NVAX) - 2023 Q3 - Earnings Call Presentation

novavax: ...... Q3 2023 • Total revenue primarily driven by $165 million in grant revenue Q3 2022 | --- | --- | --- | --- | --- | |-------------------------------------------|-------|---------|-------|---------| | ($ in millions, except per share amounts) | | Q3 2023 | | Q3 2022 | | Product sales | $| 2 |$ | 626 | | Grants | | 1 65 | | IOR | | Royalties and other | | 20 | | 2 | | Total revenue | | 187 | | 735 | | Cost of sales | | 99 | | 435 | | Research and development | | 106 | | 304 | | Selling, genera ...